Intra-Cellular Therapies (ITCI) PT Raised to $38 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Intra-Cellular Therapies (ITCI) PT Raised to $28 at SunTrust Robinson Humphrey; 'Adding Back Bipolar Depression'
March 2, 2018 9:03 AM ESTSunTrust Robinson Humphrey raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $22.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "Intra-Cellular will have a pre-NDA meeting with the FDA in 1Q18 for lumateperone for schizophrenia. Company expects to file NDA for... More
Intra-Cellular Therapies (ITCI) PT Raised to $28 at Cowen
March 2, 2018 1:23 AM ESTCowen raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $27.00) while maintaining a Outperform rating.
... More